Metropolitan Life Insurance CO Anavex Life Sciences Corp. Transaction History

Metropolitan Life Insurance CO

$253 Million
Q2 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.55 - $6.75 $5,928 - $8,795	-1,303 Reduced 30.0%	3,040 $15,000
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $5,148 - $7,364	786 Added 22.1%	4,343 $28,000
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $4,975 - $7,026	-598 Reduced 14.39%	3,557 $30,000
Q4 2022 Jun 14, 2023	BUY	$7.65 - $14.43 $4,574 - $8,629	598 Added 16.81%	4,155 $38.5 Million
Q3 2022 Jun 14, 2023	BUY	$8.9 - $12.86 $5,322 - $7,690	598 Added 16.81%	4,155 $42.9 Million
Q2 2022 Jun 20, 2023	BUY	$7.31 - $12.84 $4,371 - $7,678	598 Added 16.81%	4,155 $41,000
Q1 2022 Jun 20, 2023	BUY	$9.74 - $17.69 $5,824 - $10,578	598 Added 16.81%	4,155 $51,000
Q1 2022 Mar 30, 2023	SELL	$9.74 - $17.69 $132,688 - $240,990	-13,623 Reduced 76.63%	4,155 $51,000
Q1 2022 May 12, 2022	SELL	$9.74 - $17.69 $132,688 - $240,990	-13,623 Reduced 76.63%	4,155 $51,000
Q4 2021 Jun 21, 2023	BUY	$16.88 - $23.31 $240,050 - $331,491	14,221 Added 399.8%	17,778 $308,000
Q3 2021 Jun 21, 2023	BUY	$16.82 - $25.75 $239,197 - $366,190	14,221 Added 399.8%	17,778 $319,000
Q2 2021 Jun 21, 2023	BUY	$10.16 - $28.86 $144,485 - $410,418	14,221 Added 399.8%	17,778 $406,000
Q2 2021 Mar 30, 2023	BUY	$10.16 - $28.86 $16,184 - $45,973	1,593 Added 9.84%	17,778 $406,000
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $180,461 - $512,611	17,762 Added 111012.5%	17,778 $406,000
Q1 2021 Jun 26, 2023	BUY	$5.17 - $16.13 $65,286 - $203,689	12,628 Added 355.02%	16,185 $242 Million
Q1 2021 Mar 30, 2023	BUY	$5.17 - $16.13 $54,403 - $169,735	10,523 Added 185.85%	16,185 $241,000
Q1 2021 May 14, 2021	SELL	$5.17 - $16.13 $29,189 - $91,069	-5,646 Reduced 99.72%	16 $242,000
Q4 2020 Jun 22, 2023	BUY	$4.01 - $7.58 $8,441 - $15,955	2,105 Added 59.18%	5,662 $30,000
Q4 2020 Mar 30, 2023	BUY	$4.01 - $7.58 $9,010 - $17,032	2,247 Added 65.8%	5,662 $30,000
Q4 2020 Feb 16, 2021	BUY	$4.01 - $7.58 $9,010 - $17,032	2,247 Added 65.8%	5,662 $31,000
Q3 2020 Jun 26, 2023	SELL	$3.8 - $5.0 $539 - $710	-142 Reduced 3.99%	3,415 $15,000
Q3 2020 Mar 30, 2023	SELL	$3.8 - $5.0 $54,606 - $71,850	-14,370 Reduced 80.8%	3,415 $15,000
Q3 2020 Nov 13, 2020	SELL	$3.8 - $5.0 $54,606 - $71,850	-14,370 Reduced 80.8%	3,415 $16,000
Q2 2020 Jun 26, 2023	BUY	$2.62 - $5.2 $37,277 - $73,985	14,228 Added 400.0%	17,785 $87,000
Q2 2020 Mar 30, 2023	BUY	$2.62 - $5.2 $35,710 - $70,876	13,630 Added 328.04%	17,785 $87,000
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $46,596 - $92,482	17,785 New	17,785 $88,000

Others Institutions Holding AVXL

# of Institutions

152

Shares Held

26.5M

Call Options Held

674K

Put Options Held

811K

Black Rock Inc. New York, NY

6.39M
Shares

$36.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.55M
Shares

$25.8 Million
0.0% of portfolio
State Street Corp Boston, MA

3.74M
Shares

$21.2 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.83M
Shares

$10.4 Million
0.0% of portfolio
Two Sigma Investments, LP New York, NY

1.01M
Shares

$5.75 Million
0.01% of portfolio

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $443M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account